BioCentury | Apr 18, 2019
Financial News

RNA-targeting small molecule company Arrakis raises $75M series B

...Thursday named Paul Wotton CEO. Wotton has been CEO of Sigilon Therapeutics Inc. (Cambridge, Mass.); Ocata Therapeutics Inc....
BioCentury | Aug 17, 2018
Company News

Astellas acquires ophthalmic company Quethera

...cell therapy to deliver RGCs. The pharma acquired the program through its 2016 acquisition of Ocata Therapeutics Inc....
BioCentury | Aug 10, 2018
Company News

Astellas acquires ophthalmic company Quethera

...cell therapy to deliver RGCs. The pharma acquired the program through its 2016 acquisition of Ocata Therapeutics Inc....
BioCentury | Sep 29, 2017
Strategy

Bridge to innovation

...another example. VcanBio recruited the former senior director of research at Boston cell therapy company Ocata Therapeutics Inc....
BioCentury | Apr 13, 2016
Company News

Management tracks

...Inc. (NASDAQ:AMAG) hired Edward Myles as SVP and CFO. Myles was CFO and COO at Ocata Therapeutics Inc....
BioCentury | Feb 15, 2016
Company News

Ocata Therapeutics, Astellas deal

...Astellas completed its acquisition of Ocata for $8.50 per share (see BioCentury, Nov. 16, 2015). Ocata Therapeutics Inc....
BioCentury | Nov 16, 2015
Company News

Ocata Therapeutics, Astellas deal

...Phase I testing to treat myopic macular degeneration. The companies did not respond to inquiries. Ocata Therapeutics Inc....
BioCentury | Nov 11, 2015
Top Story

Astellas buying Ocata for $379M

...Astellas Pharma Inc. (Tokyo:4503) announced late Monday night that it will acquire cell therapy company Ocata Therapeutics Inc....
...counsel. Jefferies is Ocata's financial advisor and Goodwin Procter LLP is its counsel. Ocata (formerly Advanced Cell Technology...
BioCentury | Sep 28, 2015
Clinical News

Retinal pigment epithelial: Phase II started

...therapy prior to surgery and then different immune suppression regimens following transplantation of RPE cells. Ocata Therapeutics Inc....
BioCentury | Aug 24, 2015
Financial News

Ocata Therapeutics completes debt financing

Ocata Therapeutics Inc. (NASDAQ:OCAT), Marlborough, Mass. Business: Gene/Cell therapy, Ophthalmic Date completed: 2015-08-19 Type: Debt financing Raised: $6 million Investor: Silicon Valley Bank Note: Ocata drew down $6 million of a new $10 million loan....
Items per page:
1 - 10 of 172
BioCentury | Apr 18, 2019
Financial News

RNA-targeting small molecule company Arrakis raises $75M series B

...Thursday named Paul Wotton CEO. Wotton has been CEO of Sigilon Therapeutics Inc. (Cambridge, Mass.); Ocata Therapeutics Inc....
BioCentury | Aug 17, 2018
Company News

Astellas acquires ophthalmic company Quethera

...cell therapy to deliver RGCs. The pharma acquired the program through its 2016 acquisition of Ocata Therapeutics Inc....
BioCentury | Aug 10, 2018
Company News

Astellas acquires ophthalmic company Quethera

...cell therapy to deliver RGCs. The pharma acquired the program through its 2016 acquisition of Ocata Therapeutics Inc....
BioCentury | Sep 29, 2017
Strategy

Bridge to innovation

...another example. VcanBio recruited the former senior director of research at Boston cell therapy company Ocata Therapeutics Inc....
BioCentury | Apr 13, 2016
Company News

Management tracks

...Inc. (NASDAQ:AMAG) hired Edward Myles as SVP and CFO. Myles was CFO and COO at Ocata Therapeutics Inc....
BioCentury | Feb 15, 2016
Company News

Ocata Therapeutics, Astellas deal

...Astellas completed its acquisition of Ocata for $8.50 per share (see BioCentury, Nov. 16, 2015). Ocata Therapeutics Inc....
BioCentury | Nov 16, 2015
Company News

Ocata Therapeutics, Astellas deal

...Phase I testing to treat myopic macular degeneration. The companies did not respond to inquiries. Ocata Therapeutics Inc....
BioCentury | Nov 11, 2015
Top Story

Astellas buying Ocata for $379M

...Astellas Pharma Inc. (Tokyo:4503) announced late Monday night that it will acquire cell therapy company Ocata Therapeutics Inc....
...counsel. Jefferies is Ocata's financial advisor and Goodwin Procter LLP is its counsel. Ocata (formerly Advanced Cell Technology...
BioCentury | Sep 28, 2015
Clinical News

Retinal pigment epithelial: Phase II started

...therapy prior to surgery and then different immune suppression regimens following transplantation of RPE cells. Ocata Therapeutics Inc....
BioCentury | Aug 24, 2015
Financial News

Ocata Therapeutics completes debt financing

Ocata Therapeutics Inc. (NASDAQ:OCAT), Marlborough, Mass. Business: Gene/Cell therapy, Ophthalmic Date completed: 2015-08-19 Type: Debt financing Raised: $6 million Investor: Silicon Valley Bank Note: Ocata drew down $6 million of a new $10 million loan....
Items per page:
1 - 10 of 172